Cullinan Oncology, Inc. (CGEM)

Cullinan Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	0	18.94	0	0
Gross Profit	0	0	0	18.94	0	0
Selling, General & Admin	44.18	42.49	40.19	29.15	17.12	5.48
Research & Development	126.71	148.16	91.95	57.75	43.21	16.79
Other Operating Expenses	0.44	0.44	-276.79	0	0	0
Operating Expenses	171.32	191.09	-144.65	86.9	60.34	22.27
Operating Income	-171.32	-191.09	144.65	-67.95	-60.34	-22.27
Other Expense / Income	-24.85	-23.81	-8.69	-2.38	-8.54	-1.61
Pretax Income	-146.47	-167.28	153.34	-65.57	-51.8	-20.66
Income Tax	-14.12	-14.12	42.12	0	0	0
Net Income	-132.35	-153.16	111.21	-65.57	-51.8	-20.66
Shares Outstanding (Basic)	43	42	45	43	20	6
Shares Outstanding (Diluted)	43	42	47	43	20	6
Shares Change	5.72%	-10.91%	8.27%	116.61%	210.86%	150.89%
EPS (Basic)	-3.13	-3.69	2.46	-1.52	-2.60	-3.23
EPS (Diluted)	-3.13	-3.69	2.38	-1.52	-2.60	-3.23
Free Cash Flow	-121.57	-134.48	-127.71	-43.43	-29.78	-20.92
Free Cash Flow Per Share	-2.83	-3.24	-2.83	-1.01	-1.50	-3.27
Gross Margin	-	-	-	100.00%	-	-
Operating Margin	-	-	-	-358.73%	-	-
Profit Margin	-	-	-	-346.14%	-	-
Free Cash Flow Margin	-	-	-	-229.28%	-	-
Effective Tax Rate	-	-	27.47%	-	-	-
EBITDA	-146.16	-166.97	153.43	-65.52	-51.74	-20.59
EBITDA Margin	-	-	-	-345.86%	-	-
Depreciation & Amortization	0.31	0.31	0.09	0.05	0.06	0.07
EBIT	-146.47	-167.28	153.34	-65.57	-51.8	-20.66
EBIT Margin	-	-	-	-346.14%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).